Agilent Technologies, Inc. announced that it will acquire privately-held Advanced Analytical Technologies, Inc. (AATI) for $250 million in cash. This acquisition will enhance Agilent’s existing expertise and technology, while giving customers a better set of solutions.
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of innovation, Agilent instruments, software, services, solutions, and it provide trusted answers to its customer’s most challenging questions.
Advance Analytical Technologies (AATI) develops and sells capillary electrophoresis (CE) instruments, reagents, and software for nucleic acid analysis. The company’s instruments use parallel CE with UV absorbance of fluorescence detection for applications such as next-generation sequencing library quality control, CRISPR/Cas9 mutation detection, oligonucleotide purity assessment, and genomic DNA analysis.
Innovative solution for the Customers
Stefan Schuette, vice president and general manager of Agilent’s liquid phase separations division said that Technology advancement in genomics, metabolomics, and proteomics are driving growth and demand for innovative new solutions. The value of this acquisition is the expanded capabilities for emerging applications that Agilent and AATI together can offer to the world.
Steven J. Lasky, AATI CEO said Every company brings expertise and a culture of innovation, but he believe that they would be able to serve  better customer satisfaction and provide even greater opportunities for our employees by joining Agilent.
